(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Solar storms have influenced our history – an environmental historian explains how they could also threaten our future - 2RFK Jr. guts the US childhood vaccine schedule despite its decades-long safety record
- 3Get To Be familiar with The Historical backdrop Of Western Medication
- 4The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior
- 5Nuno Loureiro, MIT physicist, fatally shot at home; police investigate
- Figure out How to Get a good deal on Your Rooftop Substitution Venture
- New law puts familiar drinks, creams and gummies in legal limbo
- Russia accidentally destroys its only way of sending astronauts to space
- Pick Your Favored kind of sandwich
- Turkiye’s Erdogan calls Israel’s Somaliland recognition ‘unacceptable’
- RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- AI is providing emotional support for employees – but is it a valuable tool or privacy threat?
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
